West Pharmaceutical Services, Inc. (WST)
Healthcare · Medical - Instruments & Supplies · Data as of 2026-10-22
Bottom line
WST is trading at a premium to its history, near its historical resistance zone, and recent volume suggests money flowing in. The picture is mixed, so it may be worth watching rather than acting on. Past patterns are not a guarantee of future results.
Valuation — Trading at a premium (Red)
WST trades at 49× earnings, roughly in line with its own 5-year average of 46× and above similar healthcare companies we track (28×, 53 peers). Investors are currently paying more per dollar of earnings than usual. Its free-cash-flow yield is about 1.6%. Its current multiple sits around the 86th percentile of its own last five years — near the top of its own range. About 79% of its reported earnings arrived as free cash over the last year.
Price zones — Near its historical resistance zone (Red)
At $394.03, the stock is close to the upper end of its recent range. Over the past year WST has traded between $223.83 and $397.16; its historical support zone sits near $361.15 and resistance near $397.16. It is above both its 50- and 200-day averages, which has historically signalled an uptrend.
52-week range $223.83–$397.16 · 50-day average $361.15 · 200-day average $309.53
Money flow — Money is flowing in (Green)
Recent trading in WST shows more volume on rising days than falling days, a pattern often described as accumulation. Volume on up days has been about 1.5× volume on down days over the last 30 sessions.
Dividends & company facts
WST paid $0.88 a share in dividends over the past year — 0.22% of today's price — and has raised it in each of the last five years. It returned more through buybacks: $116 million in fiscal 2025, about 0.42% of its market value.
- Dividend yield (12 months)
- 0.22%
- Paid over 12 months
- $0.88 a share
- Payout ratio
- 11.0%
- Buybacks
- 0.42% (fiscal 2025)
- Shares, past year
- -2.1%
- Revenue, 12 months
- $3.3B
- Profit, 12 months
- $565M
- Employees
- 10,800
- CEO
- Michel Lagarde
- Headquarters
- Exton, PA
- Listed since
- 1980 · NYSE
About the company
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products.
Related stocks
一句话结论
WST 相对自身历史处于溢价水平，接近其历史阻力区，近期成交量显示资金正在流入。整体情况好坏参半，也许更适合先观察，而不是急于行动。过去的形态并不能保证未来的结果。
估值 — 相对自身历史处于溢价水平
WST 目前的市盈率为 49×，大致持平于其自身 5 年平均的 46×，并且高于我们追踪的同类Healthcare公司（28×，53 家）。投资者目前为每一美元盈利付出的价格高于以往。其自由现金流收益率约为 1.6%。它当前的估值倍数大约位于自身过去五年分布的第 86 百分位——接近自身区间的顶部。过去一年，其报告利润中约有 79% 转化为自由现金。
价格区间 — 接近其历史阻力区
目前价格为 $394.03，接近其近期区间的上沿。过去一年 WST 的价格在 $223.83 到 $397.16 之间波动；其历史支撑区在 $361.15 附近，阻力区在 $397.16 附近。它同时位于 50 日和 200 日均线上方，这在历史上通常对应上升趋势。
资金流向 — 资金正在流入
WST 近期上涨日的成交量高于下跌日，这种形态常被称为吸筹。过去 30 个交易日，上涨日的成交量约为下跌日的 1.5×。
股息与公司概况
WST 过去一年每股派息 0.88 美元，相当于当前股价的 0.22%，过去五年每年都有上调。它通过回购返还了更多：2025 财年回购 1.2亿美元，约占市值的 0.42%。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.